|
1
|
Jemal A, Bray F, Center MM, et al: Global
cancer statistics. CA Cancer J Clin. 61:69–90. 2011.
|
|
2
|
Houghton J, Stoicov C, Nomura S, et al:
Gastric cancer originating from bone marrow-derived cells. Science.
306:1568–1571. 2004.
|
|
3
|
Zheng L, Wang L, Ajani J and Xie K:
Molecular basis of gastric cancer development and progression.
Gastric Cancer. 7:61–77. 2004.
|
|
4
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005.
|
|
5
|
Lee Y, Ahn C, Han J, et al: The nuclear
RNase III Drosha initiates microRNA processing. Nature.
425:415–419. 2003.
|
|
6
|
Lu J, Getz G, Miska EA, et al: MicroRNA
expression profiles classify human cancers. Nature. 435:834–838.
2005.
|
|
7
|
Ma L, Teruya-Feldstein J and Weinberg RA:
Tumour invasion and metastasis initiated by microRNA-10b in breast
cancer. Nature. 449:682–688. 2007.
|
|
8
|
Yanaihara N, Caplen N, Bowman E, et al:
Unique microRNA molecular profiles in lung cancer diagnosis and
prognosis. Cancer Cell. 9:189–198. 2006.
|
|
9
|
Schaefer A, Jung M, Mollenkopf HJ, et al:
Diagnostic and prognostic implications of microRNA profiling in
prostate carcinoma. Int J Cancer. 126:1166–1176. 2010.
|
|
10
|
Kim YK, Yu J, Han TS, et al: Functional
links between clustered microRNAs: suppression of cell-cycle
inhibitors by microRNA clusters in gastric cancer. Nucleic Acids
Res. 37:1672–1681. 2009.
|
|
11
|
Zhang J, Yang Y, Yang T, et al:
microRNA-22, downregulated in hepatocellular carcinoma and
correlated with prognosis, suppresses cell proliferation and
tumourigenicity. Br J Cancer. 103:1215–1220. 2010.
|
|
12
|
Friedman JM, Jones PA and Liang G: The
tumor suppressor microRNA-101 becomes an epigenetic player by
targeting the polycomb group protein EZH2 in cancer. Cell Cycle.
8:2313–2314. 2009.
|
|
13
|
Kefas B, Godlewski J, Comeau L, et al:
microRNA-7 inhibits the epidermal growth factor receptor and the
Akt pathway and is down-regulated in glioblastoma. Cancer Res.
68:3566–3572. 2008.
|
|
14
|
Marquez RT, Wendlandt E, Galle CS, Keck K
and McCaffrey AP: MicroRNA-21 is upregulated during the
proliferative phase of liver regeneration, targets Pellino-1, and
inhibits NF-kappaB signaling. Am J Physiol Gastrointest Liver
Physiol. 298:G535–G541. 2010.
|
|
15
|
Sun H, Li QW, Lv XY, et al: MicroRNA-17
post-transcriptionally regulates polycystic kidney disease-2 gene
and promotes cell proliferation. Mol Biol Rep. 37:2951–2958.
2010.
|
|
16
|
Lowery AJ, Miller N, Dwyer RM and Kerin
MJ: Dysregulated miR-183 inhibits migration in breast cancer cells.
BMC Cancer. 10:5022010.
|
|
17
|
Zhao H, Guo M, Zhao G, et al: miR-183
inhibits the metastasis of osteosarcoma via downregulation of the
expression of Ezrin in F5M2 cells. Int J Mol Med. 30:1013–1020.
2012.
|
|
18
|
Sarver AL, Li L and Subramanian S:
MicroRNA miR-183 functions as an oncogene by targeting the
transcription factor EGR1 and promoting tumor cell migration.
Cancer Res. 70:9570–9580. 2010.
|
|
19
|
Liu K, Li G, Fan C, et al: Increased
Expression of MicroRNA-221 in Gastric Cancer and Its Clinical
Significance. J Int Med Res. 40:467–474. 2012.
|
|
20
|
Zhao X, Dou W, He L, et al: MicroRNA-7
functions as an anti-metastatic microRNA in gastric cancer by
targeting insulin-like growth factor-1 receptor. Oncogene.
32:1363–1372. 2013.
|
|
21
|
Li Z, Cao Y, Jie Z, et al: miR-495 and
miR-551a inhibit the migration and invasion of human gastric cancer
cells by directly interacting with PRL-3. Cancer Lett. 323:41–47.
2012.
|
|
22
|
Carvalho J, van Grieken NC, Pereira PM, et
al: Lack of microRNA-101 causes E-cadherin functional deregulation
through EZH2 up-regulation in intestinal gastric cancer. J Pathol.
228:31–44. 2012.
|
|
23
|
Gao P, Xing AY, Zhou GY, et al: The
molecular mechanism of microRNA-145 to suppress invasion-metastasis
cascade in gastric cancer. Oncogene. 32:491–501. 2013.
|
|
24
|
Zhu J, Feng Y, Ke Z, et al:
Down-regulation of miR-183 promotes migration and invasion of
osteosarcoma by targeting Ezrin. Am J Pathol. 180:2440–2451.
2012.
|
|
25
|
Ueno K, Hirata H, Shahryari V, et al:
microRNA-183 is an oncogene targeting Dkk-3 and SMAD4 in prostate
cancer. Br J Cancer. 108:1659–1667. 2013.
|
|
26
|
Zhou T, Zhang GJ, Zhou H, Xiao HX and Li
Y: Overexpression of microRNA-183 in human colorectal cancer and
its clinical significance. Eur J Gastroenterol Hepatol. 26:229–223.
2014.
|
|
27
|
Zhu W, Liu X, He J, et al: Overexpression
of members of the microRNA-183 family is a risk factor for lung
cancer: a case control study. BMC Cancer. 11:3932011.
|
|
28
|
Tanaka H, Sasayama T, Tanaka K, et al:
MicroRNA-183 upregulates HIF-1alpha by targeting isocitrate
dehydrogenase 2 (IDH2) in glioma cells. J Neurooncol. 111:273–283.
2013.
|
|
29
|
Kang MK, Kim RH, Kim SJ, et al: Elevated
Bmi-1 expression is associated with dysplastic cell transformation
during oral carcinogenesis and is required for cancer cell
replication and survival. Br J Cancer. 96:126–133. 2007.
|
|
30
|
He S, Iwashita T, Buchstaller J, et al:
Bmi-1 over-expression in neural stem/progenitor cells increases
proliferation and neurogenesis in culture but has little effect on
these functions in vivo. Dev Biol. 328:257–272. 2009.
|
|
31
|
Douglas D, Hsu JH, Hung L, et al: BMI-1
promotes ewing sarcoma tumorigenicity independent of CDKN2A
repression. Cancer Res. 68:6507–6515. 2008.
|
|
32
|
Liu JH, Song LB, Zhang X, et al: Bmi-1
expression predicts prognosis for patients with gastric carcinoma.
J Surg Oncol. 97:267–272. 2008.
|
|
33
|
Lu H, Sun HZ, Li H and Cong M: The
clinicopathological significance of Bmi-1 expression in
pathogenesis and progression of gastric carcinomas. Asian Pac J
Cancer Prev. 13:3437–3441. 2012.
|
